Get started
Connect Biopharma Holdings LimitedConnect Biopharma Holdings LimitedConnect Biopharma Holdings Limited

Connect Biopharma Holdings Limited

No trades
See on Supercharts
OverviewFinancialsNewsDocumentsIdeasDiscussionsTechnicalsForecastSeasonalsOptions

CNTB chart


Full chart

CNTB upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪87.48 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.28 USD
Net income (FY)
‪−15.63 M‬ USD
Revenue (FY)
‪26.03 M‬ USD
Shares float
—
Beta (1Y)
0.45

Employees


Employees (FY)
62
Change (1Y)
−19 −23.46%
Revenue / Employee (1Y)
‪419.89 K‬ USD
Net income / Employee (1Y)
‪−252.06 K‬ USD

About Connect Biopharma Holdings Limited


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Barry D. Quart
Website
connectbiopharm.com
Headquarters
San Diego
Founded
2015
ISIN
KYG235491019
FIGI
BBG00ZGYNJ49
Connect Biopharma Holdings Ltd. operates as clinical-stage biopharmaceutical company. It focuses on advancing rademikibart, an anti-interleukin-4-receptor alpha antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease. The company was founded by Zheng Wei and Wu Bin Pan on November 23, 2015 and is headquartered in San Diego, CA.

Check out other big names from the same industry as CNTB.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

CNTB news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CNTB is 1.57 USD — it has decreased by −2.48% in the past 24 hours. Watch Connect Biopharma Holdings Limited stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Connect Biopharma Holdings Limited stocks are traded under the ticker CNTB.
CNTB stock has fallen by −4.04% compared to the previous week, the month change is a −7.65% fall, over the last year Connect Biopharma Holdings Limited has showed a 25.83% increase.
We've gathered analysts' opinions on Connect Biopharma Holdings Limited future price: according to them, CNTB price has a max estimate of 7.50 USD and a min estimate of 6.04 USD. Watch CNTB chart and read a more detailed Connect Biopharma Holdings Limited stock forecast: see what analysts think of Connect Biopharma Holdings Limited and suggest that you do with its stocks.
CNTB reached its all-time high on Aug 10, 2021 with the price of 29.27 USD, and its all-time low was 0.51 USD and was reached on Apr 4, 2025. View more price dynamics on CNTB chart.
See other stocks reaching their highest and lowest prices.
CNTB stock is 5.77% volatile and has beta coefficient of 0.45. Track Connect Biopharma Holdings Limited stock price on the chart and check out the list of the most volatile stocks — is Connect Biopharma Holdings Limited there?
Yes, you can track Connect Biopharma Holdings Limited financials in yearly and quarterly reports right on TradingView.
Connect Biopharma Holdings Limited is going to release the next earnings report on Dec 3, 2025. Keep track of upcoming events with our Earnings Calendar.
CNTB earnings for the last quarter are −0.23 USD per share, whereas the estimation was −0.22 USD resulting in a −4.55% surprise. The estimated earnings for the next quarter are −0.24 USD per share. See more details about Connect Biopharma Holdings Limited earnings.
Connect Biopharma Holdings Limited revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
CNTB net income for the last quarter is ‪−12.90 M‬ USD, while the quarter before that showed ‪−10.27 M‬ USD of net income which accounts for −25.57% change. Track more Connect Biopharma Holdings Limited financial stats to get the full picture.
No, CNTB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 21, 2025, the company has 62 employees. See our rating of the largest employees — is Connect Biopharma Holdings Limited on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Connect Biopharma Holdings Limited EBITDA is ‪−21.79 M‬ USD, and current EBITDA margin is −83.71%. See more stats in Connect Biopharma Holdings Limited financial statements.
Like other stocks, CNTB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Connect Biopharma Holdings Limited stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Connect Biopharma Holdings Limited technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Connect Biopharma Holdings Limited stock shows the neutral signal. See more of Connect Biopharma Holdings Limited technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.